NES-1 polypeptides, DNA, and related molecules and methods

• US 7,033,746 B2
• Filed: 12/12/2001
• Issued: 04/25/2006
• Est. Priority Date: 06/06/1995
• Status: Expired due to Fees

• Current Assignee: New England Medical Center Hospitals, Inc.
• Original Assignee: New England Medical Center Hospitals, Inc.
• Inventors: Band, Vimla
• Primary Examiner(s): Nashed, Nashaat T.
• Application Number:
  US10/021,368
• Publication Number:
  US 20020106367A1
• Time in Patent Office: 1,595 Days
• Field of Search: 435/6, 435/23, 435/219, 536/23.2, 536/23.5
• US Class Current: 435/4
• CPC Class Codes: C12N 9/6424 Serine endopeptidases (3.4.21)

Abstract

Disclosed is substantially pure NES1 polypeptide and purified DNA, vectors, and cells encoding that polypeptide. Also disclosed are methods for carcinoma detection and treatment using the NES1 sequence.

Claims

1. A method of determining whether a human has a carcinoma or an increased likelihood of developing a carcinoma, the method comprising:

(a) providing a biological sample from the human, wherein the biological sample comprises a Normal Epithelial Specific-1(NES1) gene, the expression of which is down-regulated during tumorigenic progression and the sequence of which comprises a coding sequence that encodes a polypeptide that is at least 95% identical to SEQ ID NO;

1; and

(b) examining the expression of the NES1 gene in the biological sample, wherein a decrease in the expression of the NES1 gene relative to expression of a NES1 gene in a control biological sample indicates that the human has a carcinoma or an increased likelihood of developing a carcinoma.

2. The method of claim 1, wherein the biological sample comprises an epithelial cell.

3. The method of claim 1, wherein the biological sample comprises a breast tissue cell.

4. The method of claim 1, wherein the biological sample comprises a cervical tissue cell.

5. The method of claim 1, wherein the biological sample comprises a prostate tissue cell.

6. The method of claim 1, wherein the expression of the NES1 gene is determined by assaying NES1 mRNA expression.

7. The method of claim 1, wherein the expression of the NES1 gene is determined by assaying NES1 protein expression.

8. The method of claim 1, wherein the biological sample comprises a cell of the skin, large intestine, lung, liver, brain, kidney, ovary, uterus, stomach, esophagus, nasopharynx, larynx, or a glandular tissue.

9. The method of claim 1, wherein the control biological sample is (a) an equivalent biological sample from an unaffected individual;

(b) an unaffected biological sample of a similar tissue type from the human;

or (c) a standard representing a wild-type level of NES1 expression.

10. A method of determining whether a human has a carcinoma or an increased likelihood of developing a carcinoma, the method comprising:

(a) providing a biological sample from the human, wherein the biological sample comprises a NES1 gene, the expression of which is down-regulated during tumorigenic progression and the sequence of which comprises a coding sequence that is at least 95% identical to SEQ ID NO;

2; and

(b) examining the expression of the NES1 gene in the biological sample, wherein a decrease in the expression of the NES1 gene relative to expression of an NES1 gene in a control biological sample indicates that the human has a carcinoma or an increased likelihood of developing a carcinoma.

11. The method of claim 10, wherein the biological sample comprises an epithelial cell.

12. The method of claim 10, wherein the biological sample comprises a breast tissue cell.

13. The method of claim 10, wherein the biological sample comprises a cervical tissue cell.

14. The method of claim 10, wherein the biological sample comprises a prostate tissue cell.

15. The method of claim 10, wherein the expression of the NES1 gene is determined by assaying NES1 mRNA expression.

16. The method of claim 10, wherein the expression of the NES1 gene is determined by assaying NES1 protein expression.

17. The method of claim 10, wherein the biological sample comprises a cell of the skin, large intestine, lung, liver, brain, kidney, ovary, uterus, stomach, esophagus, nasopharynx, larynx, or a glandular tissue.

18. The method of claim 10, wherein the control biological sample is (a) an equivalent biological sample from an unaffected individual;

(b) an unaffected biological sample of a similar tissue type from the human;

or (c) a standard representing a wild-type level of NES1 expression.